– USA, TX – Lung Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the orphan, pulmonary diseases and conditions, today announced the appointment of Bill Fairey to its Board of Directors, bringing 30 years of experience building strong and scalable global commercial organizations.
“We are pleased that Bill Fairey has joined Lung Therapeutics’ Board of Directors. He brings a wealth of biopharmaceutical leadership and broad commercial expertise that will advance Lung Therapeutics’ strategy as we move through later stage development and into commercialization.” said CEO, Dr. Brian Windsor.
About Bill Fairey
Fairey’s extensive background includes serving as EVP and Chief Commercial Officer at MyoKardia, where he built the company’s commercial and portfolio strategy and established the European headquarters. As ChemoCentryx COO he was responsible for building out the initial commercial and medical teams. Before ChemoCentryx, Fairey served in several roles at Actelion Pharmaceuticals, including developing Actelion’s Asia-Pacific business; chairing the Actelion China Board of Directors; serving as President of Actelion Canada, and becoming President of the U.S. division. He has served on the boards of the California Life Sciences Association and Rx&D, an association of Canada’s research-based pharmaceutical companies.
“I am looking forward to working with the outstanding team at Lung Therapeutics. The company is developing promising and novel therapeutics that may help improve the lives of patients with serious forms of rare lung diseases,” said Bill Fairey.
Fairey holds an MBA degree from Saint Mary’s College of California and a Bachelor of Science degree in Biology from the University of Oregon.
About Lung Therapeutics, Inc.
Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical-stage biopharmaceutical company formed to leverage leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing a proprietary pipeline of novel therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead drug LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US. LTI-01 is currently in Phase 2, a randomized, placebo-controlled, double-blind, dose-ranging study evaluating LTI-01 in patients with infected, non-draining loculated pleural effusions. The company’s second product candidate, LTI-03, is in development for idiopathic pulmonary fibrosis.
For more information: https://www.lungtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.